Danish Drama: Genmab Drops $8B on Cancer Cure Hope Seller
In a move that screams 'we have billionaire money to burn,' Danish biotech bigwig Genmab announced it plans to acquire Merus, the brainiac behind a shiny new head and neck cancer drug, for around $8 billion. That's $8 billion, or roughly the cost of buying every Danish pastry in Copenhagen twice over. This deal lands Genmab firmly in Life Sciences prime, scheming to turn biology into cold, hard kroner. With cancer therapy innovation like this on the line, letâs hope Merus's drug fights neck and head tumors better than Genmab fought that price tag.
Share the Story
Genmab just dropped $8 billion on Merus like itâs Black Friday for biotech, apparently 'saving cancer patients' is easier when you have a billionaire bankroll appearing out of nowhere.
Buying a head and neck cancer drug developer for $8 billion is peak pharmaceutical flexâGenmabâs basically saying, 'Weâll fix your cells, but first, show us the money.'
Genmab buying Merus is like paying $8 billion for a Tesla upgradeâyouâre still hoping it doesnât break down, but hey, it looks promising!
Source: Statnews | Published: 9/29/2025 | Author: Andrew Joseph
More Articles in Business
Politico Announces Australia Launch for 2026, Because Why Not Start Late?
Trump Promises Retirement Plan That Matches Generosity of Federal Workersâ Excuses
Trump Calls Supreme Court 'Unfortunate,' Then Hits Economy with âBetterâ 10% Global Tariff
Workday CEO Wonders Who to Replace with AI Before Deciding to Lay Off 400 Humans
David Ellisonâs 10th WBD Offer: Slightly Better Than Doing Nothing
AI Slaps White-Collar Jobs, Blue-Collars Brace for Gig Economy Chain Reaction
Costco, Toyota & FedEx Sue Trump For Tariff Refunds Like Itâs Black Friday Cashback
Lamborghini Cancels Silent EV, Citing Absence of Vroom-Feelz
